169 related articles for article (PubMed ID: 38531576)
1. Efficacy and safety of natural killer cells injection combined with XELOX chemotherapy in postoperative patients with stage III colorectal cancer in China: a prospective randomised controlled clinical trial study protocol.
Geng S; Yu X; Yu S
BMJ Open; 2024 Mar; 14(3):e080377. PubMed ID: 38531576
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
3. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
[TBL] [Abstract][Full Text] [Related]
4. CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial.
Liu F; Tong T; Huang D; Yuan W; Li D; Lin J; Cai S; Xu Y; Chen W; Sun Y; Zhuang J
BMJ Open; 2019 Jan; 9(1):e017637. PubMed ID: 30700474
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
6. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E;
Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH
J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259
[TBL] [Abstract][Full Text] [Related]
8. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
9. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.
Wang F; Qu A; Sun Y; Zhang J; Wei B; Cui Y; Liu X; Tian W; Li Y
Br J Radiol; 2021 Aug; 94(1124):20201088. PubMed ID: 34260297
[TBL] [Abstract][Full Text] [Related]
11. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y
BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662
[TBL] [Abstract][Full Text] [Related]
12. Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
Danno K; Hata T; Tamai K; Fujie Y; Ide Y; Kim HM; Ohnishi T; Morita S; Yoshioka S; Kudo T; Nishimura J; Matsuda C; Akamatsu H; Mizushima T; Nezu R; Doki Y; Mori M; ;
Cancer Chemother Pharmacol; 2017 Oct; 80(4):777-785. PubMed ID: 28825216
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial.
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Ariyoshi K; Oyamada S; Iwase S
BMJ Open; 2018 Jul; 8(7):e021442. PubMed ID: 30030317
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H
Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981
[TBL] [Abstract][Full Text] [Related]
15. Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients.
Geng R; Wang G; Qiu L; Liu B; Yang F; Zhang J; Miao Y
Medicine (Baltimore); 2020 Dec; 99(51):e23719. PubMed ID: 33371122
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
Qin S; Li J; Bai Y; Shu Y; Li W; Yin X; Cheng Y; Sun G; Deng Y; Zhong H; Li Y; Qian X; Zhang L; Zhang J; Chen K; Kang W;
BioDrugs; 2021 Jul; 35(4):445-458. PubMed ID: 34014555
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1).
Wei M; Shi S; Hua J; Xu J; Yu X;
BMJ Open; 2019 Dec; 9(12):e033452. PubMed ID: 31818843
[TBL] [Abstract][Full Text] [Related]
18. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
Bridgewater JA; Pugh SA; Maishman T; Eminton Z; Mellor J; Whitehead A; Stanton L; Radford M; Corkhill A; Griffiths GO; Falk S; Valle JW; O'Reilly D; Siriwardena AK; Hornbuckle J; Rees M; Iveson TJ; Hickish T; Garden OJ; Cunningham D; Maughan TS; Primrose JN;
Lancet Oncol; 2020 Mar; 21(3):398-411. PubMed ID: 32014119
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas.
Ni L; Zhang W; Chen Y; Leng W; Gou H; Hu J; Qiu M
Medicine (Baltimore); 2021 Apr; 100(17):e25493. PubMed ID: 33907099
[TBL] [Abstract][Full Text] [Related]
20. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
